Published in Ned Tijdschr Geneeskd on March 14, 1998
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Antigenic diversity thresholds and the development of AIDS. Science (1991) 5.13
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (1988) 3.50
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology (1991) 3.33
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ (1989) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virology (1992) 2.76
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet (1998) 2.67
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol (1992) 2.41
Neutralization of HIV-1: a paradox of humoral proportions. FASEB J (1991) 2.41
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Universal cellular tropism? Nature (1992) 2.18
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J Virol (1996) 2.17
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology (1994) 2.15
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics (1986) 2.09
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08
Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health (1988) 2.07
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06
Alternative view on AIDS. Lancet (1992) 2.06
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 2.06
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol (1982) 2.04
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02
[Therapeutic options for HIV infection should lead to increased utilization of HIV tests]. Ned Tijdschr Geneeskd (1999) 2.01
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol (2001) 1.98
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet (1998) 1.88
HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. Genitourin Med (1989) 1.88
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology (1991) 1.85
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85